Esperion Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ESPR Nasdaq 2836 www.esperion.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Esperion Therapeutics, Inc.

ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada - Dec 3rd, 2024 3:06 pm
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk - Dec 2nd, 2024 1:00 pm
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia - Nov 26th, 2024 1:00 pm
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference - Nov 21st, 2024 1:00 pm
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 - Nov 18th, 2024 3:30 pm
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Nov 8th, 2024 9:15 pm
Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... - Nov 8th, 2024 7:08 am
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y - Nov 7th, 2024 3:58 pm
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates - Nov 7th, 2024 12:10 pm
Esperion Therapeutics: Q3 Earnings Snapshot - Nov 7th, 2024 11:08 am
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update - Nov 7th, 2024 11:00 am
Esperion to Participate in Upcoming Jefferies London Healthcare Conference - Nov 4th, 2024 1:00 pm
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Oct 31st, 2024 2:01 pm
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions - Oct 31st, 2024 12:00 pm
Esperion to Report Third Quarter 2024 Financial Results on November 7 - Oct 24th, 2024 12:00 pm
Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings - Oct 17th, 2024 11:02 pm
Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5? - Oct 3rd, 2024 8:56 am
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid - Oct 2nd, 2024 12:00 pm
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Sep 25th, 2024 8:30 pm
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report? - Sep 11th, 2024 3:30 pm